This clinical trial aims to test in female patients with systemic lupus erythematosus (SLE). The main question it seeks to answer is whether etonogestrel implants can protect ovarian reserve function in patients with SLE. Participants will be randomly divided into a test group and a control group. The test group will be implanted subcutaneously with etongestrel for one year. Researchers won't intervene in the control group. After three months of drug-eluting, researchers will compare measures of ovarian reserve function in the test and control groups to see if etonogestrel implants can protect ovarian reserve function in patients with SLE.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
180
Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
Anti-Mullerian hormone (AMH) serum level
The serum AMH levels of the two groups will be compared one year and three months after enrollment.
Time frame: one year and three months
Number of antral follicle
The number of antral follicles will be recorded by transvaginal ultrasound and compared one year and three months after enrollment.
Time frame: one year and three months
Follicle-stimulating hormone (FSH) serum level
The serum FSH levels of the two groups will be compared one year and three months after enrollment.
Time frame: one year and three months
luteinizing hormone (LH) serum level
The serum LH levels of the two groups will be compared one year and three months after enrollment.
Time frame: one year and three months
Estradiol (E2) serum level
The serum E2 levels of the two groups will be compared one year and three months after enrollment.
Time frame: one year and three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.